Skip to main content

Table 4 Treatment characteristics

From: Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?

 

Non O-ILD

O-ILD

 

(n = 475)

(n = 82)

p-value

Treatment, yes (%)

   

 Bronchodilator

45 (9%)

35 (43%)

 < 0.0001

  SABA

18 (4%)

13 (16%)

 < 0.0001

  LABA

32 (7%)

18 (22%)

 < 0.0001

  LAMA

1 (0%)

17 (21%)

 < 0.0001

 ICS

40 (8%)

20 (24%)

 < 0.0001

 OCS

98 (21%)

13 (16%)

 

 Immunosuppressive therapy

76 (16%)

17 (21%)

 
  1. Bold to indicate statistically significant p values
  2. Among non O-ILD patients, 31 (7%) received a double therapy LABA/ICS. Among O-ILD patients, 9 (11%) received a double therapy LABA/ICS, 2 (2%) a double therapy LABA /LAMA and 7 (8%) a triple therapy (LABA/LAMA/ICS)
  3. LABA long-acting B2-agonists, LAMA long-acting muscarinic antagonist, ICS inhaled corticosteroids, ILD interstitial lung disease, O-ILD obstructive-interstitial lung disease, OCS oral corticosteroids, SABA short acting B2 agonists
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us